EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 251 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR 15% of People With Lung Cancer Have an Inherited Mutation for... August 15, 2022 EMA Recommends Extension of Therapeutic Indications for Darolutamide August 7, 2025 Five Questions With…Jessica, Katie, and Melanie July 21, 2022 Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... December 14, 2021 Load more HOT NEWS How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective Telehealth Can Save People with Cancer Time, Travel, and Money Patients With DCIS Reduce Risk Of Recurrence And Death If They... Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer?
